Henning Afflerbach
Administration
Scil Proteins
Germany
Biography
Henning Afflerbach was appointed CEO of Scil Proteins in 2013. In this role he is now focusing exclusively on the commercialization of the company’s proprietary Affilin® platform. He originally joined the company in 2009, as CBO, and was responsible for leading the business development as well as strategic planning for both Scil Proteins and Scil Proteins Production. Dr. Afflerbach has a broad range of experiences gained through his various roles in the biopharma industries including business development, strategic planning and administration at Peptor GmbH/Ltd (Rehovot, Israel/Erkrath, Germany), Develogen AG (Göttingen, Germany), and DIREVO Biotech AG (Cologne, Germany). He has a track record that spans multi-national licensing, service deal making and strategic partnering as well as merger and acquisition activities with global pharmaceutical and biotechnology companies. Dr. Afflerbach received his PhD in Biophysics from the Heinrich-Heine University of Düsseldorf.
Research Interest
Biophysics
